The White House Office of National Drug Control Policy warned on April 30, 2026 that opioid cychlorphine is appearing in counterfeit medications and mixed drug supplies. The drug has already been linked to at least 55 overdose deaths nationwide, raising the risk for people who think they are taking a familiar pill.
The warning matters most for people buying look-alike tablets sold as Xanax or other medications. A 2026 case report highlighted by the American College of Medical Toxicology described a woman in her twenties who took what she thought was alprazolam, became unresponsive, and developed respiratory depression before later testing showed cychlorphine.
ONDCP April 30 warning
The office said cychlorphine is an emerging synthetic opioid and identified it as a new dangerous drug on April 30, 2026. It described the substance as showing up in street-manufactured counterfeit pharmaceuticals and in mixed drug supplies, where it can be taken without the user knowing it is present.
Cychlorphine also goes by N-propionitrile chlorphine. The White House Office of National Drug Control Policy said it has been identified in look-alike counterfeit versions of Ritalin, Percocet, Dilaudid, Xanax, and OxyContin, and often appears mixed with fentanyl, methamphetamine, cocaine, bromazolam, and other substances.
Tyler Woods review
Tyler Woods reviewed the Psychology Today article that carried the warning update. The article says cychlorphine belongs to the orphine family of synthetic opioids, while the United Nations Office on Drugs and Crime classifies it as a piperidine benzimidazolone opioid that acts at μ-opioid receptors and has no approved medical use.
The United Nations Office on Drugs and Crime documented reports from ten countries and said the drug was available through international online drug markets. That wider spread helps explain why the substance can reach counterfeit pills and mixed supplies far from where it first appears.
Cychlorphine potency
The White House Office of National Drug Control Policy warned that cychlorphine may be up to ten times more potent than fentanyl. The article also says that estimate should be treated with caution because reliable human dose-response information remains limited and laboratory estimates do not substitute for real-world dosing data.
That is the practical problem for anyone who encounters a counterfeit pill: the expected dose may not match what is inside, and a person looking for alprazolam may instead absorb a potent opioid. The same risk runs in the other direction, where someone expecting an opioid can be exposed to other drugs mixed into the tablet or supply.
For people who rely on street pills or mixed supplies, the safest reading of the warning is direct: the drug supply now includes a synthetic opioid tied to at least 55 deaths, it can appear in pills sold as familiar medications, and its strength may exceed fentanyl by a wide margin. The open question is where cychlorphine is being manufactured and how it is entering counterfeit pills.
